Back to top
more

Achaogen, Inc. (AKAO)

(Delayed Data from NSDQ)

$0.11 USD

0.11
48,269,395

0.00 (0.00%)

Updated Apr 25, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Achaogen (AKAO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Achaogen (AKAO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

by Zacks Equity Research

Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

Achaogen (AKAO) Upgraded to Buy: Here's Why

by Zacks Equity Research

Achaogen (AKAO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.

Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Achaogen (AKAO) delivered earnings and revenue surprises of 8.33% and -47.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

by Zacks Equity Research

Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

    New Strong Sell Stocks for August 7th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Achaogen (AKAO) delivered earnings and revenue surprises of -30.43% and 71.95%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Options Traders Expect Huge Moves in Achaogen (AKAO) Stock

        by Zacks Equity Research

        Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

          Options Traders Expect Huge Moves in Achaogen (AKAO) Stock

          by Zacks Equity Research

          Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

            Achaogen's NDA for Plazomicin Gets Priority Review From FDA

            by Zacks Equity Research

            Achaogen's (AKAO) NDA for its urinary tract infections candidate, plazomicin, gets FDA's priority review.

              Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

              by Zacks Equity Research

              Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

                Achaogen's Plazomicin Gets Breakthrough Therapy Designation

                by Zacks Equity Research

                Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.

                  Fogo de Chao (FOGO) to Report Q4 Earnings: What's in Store?

                  by Zacks Equity Research

                  Fogo de Chao, Inc. (FOGO) is set to report fourth-quarter and full-year 2016 results on Mar 14, after market close.

                    Achaogen (AKAO) Shares March Higher, Can It Continue?

                    by Zacks Equity Research

                    Achaogen, Inc. (AKAO) has been on the move lately as the stock has risen by 23.9% in the past four weeks, and it is currently trading well above its 20-Day SMA

                      Achaogen (AKAO) Shares March Higher, Can It Continue?

                      by Zacks Equity Research

                      As of late, it has definitely been a great time to be an investor in Achaogen, Inc. (AKAO).

                        The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

                          Arpita Dutt headshot

                          4 Biotech Stocks that More than Doubled in 2016

                          by Arpita Dutt

                          Despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016.

                            Sanghamitra Saha headshot

                            Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?

                            by Sanghamitra Saha

                            Inside the changes in portfolio constituents of two BioShares Biotech ETFs.

                              New Strong Buy Stocks for July 12th

                              by Zacks Equity Research

                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday